Your browser doesn't support javascript.
loading
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.
Di, Mengyang; Potnis, Kunal C; Long, Jessica B; Isufi, Iris; Foss, Francine; Seropian, Stuart; Gross, Cary P; Huntington, Scott F.
Afiliación
  • Di M; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Potnis KC; Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University, New Haven, CT, USA.
  • Long JB; Division of Hematology and Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Isufi I; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Foss F; Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University, New Haven, CT, USA.
  • Seropian S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Gross CP; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Huntington SF; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
JNCI Cancer Spectr ; 8(4)2024 Jul 01.
Article en En | MEDLINE | ID: mdl-39115391
ABSTRACT
High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521 500), with median costs below $25 000 in all other 28-day intervals. Costs of CAR-T therapy use were substantial, largely driven by product acquisition. Future studies should examine the relationship between costs, access, and financial outcomes.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JNCI Cancer Spectr Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JNCI Cancer Spectr Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos